Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study

BACKGROUND: Bisphosphonates have exhibited anti-tumor activity in non-small cell lung cancer (NSCLC). We aimed to evaluate whether the combination of bisphosphonates with tyrosine kinase inhibitors of EGFR (EGFR-TKIs) could obtain a synergistic effect on advanced NSCLC patients with EGFR mutations....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Huang, Chu-Ying, Wang, Li, Feng, Cheng-Jun, Yu, Ping, Cai, Xiao-Hong, Yao, Wen-Xiu, Xu, Yong, Liu, Xiao-Ke, Zhu, Wen-Jiang, Wang, Yan, Zhou, Jin, Lu, You, Wang, Yong-Sheng
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341815/
https://ncbi.nlm.nih.gov/pubmed/26624882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.5515
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars